Natural Product (NP) Details
General Information of the NP (ID: NP9888) | |||||
---|---|---|---|---|---|
Name |
Acitretin
|
||||
Synonyms |
Acitretin; 55079-83-9; Etretin; Soriatane; Neotigason; all-trans-Acitretin; Acitretine; Retinoid etretin; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; Acitretina; Acitretinum; TMMP; Ro 10-1670; 13-cis-Acitretin; Ro 10-1670/000; UNII-LCH760E9T7; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; CHEBI:50173; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)-; Ro-101670000; LCH760E9T7; 54757-46-9; NCGC00163127-02; Acitretine [French]; Acitretinum [Latin]; Acitretina [Spanish]; 2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-, (all-E)-; Soriatane CK; Soriatane (TN); CCRIS 5534; Ro-10-1670; HSDB 7187; EINECS 259-474-4; CHEBI:50172; Acitretin/; U0279; all-trans-Etretin; Acitretin [USAN:USP:INN:BAN]; Acitretin,(S); 69427-46-9; Acitretin (USP/INN); Spectrum5_002065; DSSTox_CID_2553; Ro-10-1670/000; SCHEMBL3759; CHEMBL1131; DSSTox_RID_76624; DSSTox_GSID_22553; MLS001076667; BIDD:GT0617; GTPL7598; DTXSID6022553; BCPP000437; HMS2234L17; HMS3259J12; HMS3714E17; 2-Ethynyl-5-Methylpyridine1-oxide; Acitretin, >=98.0% (HPLC); HY-B0107; ZINC3798734; Tox21_112012; ABP000589; BDBM50088429; MFCD00866632; s1368; STL565770; AKOS015889991; AB07538; AC-4702; BCP9000229; CCG-220668; CS-1855; DB00459; KS-5246; NC00723; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-; NCGC00163127-01; NCGC00163127-03; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; AS-12644; SMR000499573; AB0007949; CAS-55079-83-9; SW199134-2; D02754; AB00698376-08; AB00698376_09; Acitretin 100 microg/mL in Acetonitrile:Acetone; 079A839; A830475; Q341500; SR-01000763200; SR-01000763200-3; BRD-K90699611-001-01-4; Acitretin, British Pharmacopoeia (BP) Reference Standard; Acitretin, European Pharmacopoeia (EP) Reference Standard; Acitretin, United States Pharmacopeia (USP) Reference Standard; Acitretin, Pharmaceutical Secondary Standard; Certified Reference Material; 2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2E,4E,6E,8E)-
Click to Show/Hide
|
||||
Species Origin | Homo sapiens ... | Click to Show/Hide | |||
Homo sapiens | |||||
Disease | Plaque psoriasis [ICD-11: EA90] | Approved | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C21H26O3
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
|
||||
InChI |
1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
|
||||
InChIKey |
IHUNBGSDBOWDMA-AQFIFDHZSA-N
|
||||
CAS Number |
CAS 55079-83-9
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Methotrexate | Leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | Male K14-VEGF mice (10 weeks old) were used in this study. | |||||
Experimental
Result(s) |
The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis. | |||||
Hydroxyurea | Myeloproliferative neoplasm | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Experimental
Result(s) |
Hydroxyurea and acitretin as a novel combination therapy in severe plaque psoriasis. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | STAT factor 3 (STAT3) | Molecule Info | [4] | |
KEGG Pathway | Chemokine signaling pathway | Click to Show/Hide | ||
2 | HIF-1 signaling pathway | |||
3 | FoxO signaling pathway | |||
4 | Signaling pathways regulating pluripotency of stem cells | |||
5 | Jak-STAT signaling pathway | |||
6 | Prolactin signaling pathway | |||
7 | Adipocytokine signaling pathway | |||
8 | Toxoplasmosis | |||
9 | Hepatitis C | |||
10 | Hepatitis B | |||
11 | Measles | |||
12 | Epstein-Barr virus infection | |||
13 | Pathways in cancer | |||
14 | Viral carcinogenesis | |||
15 | Proteoglycans in cancer | |||
16 | MicroRNAs in cancer | |||
17 | Pancreatic cancer | |||
18 | Acute myeloid leukemia | |||
19 | Inflammatory bowel disease (IBD) | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | EGF receptor signaling pathway | |||
3 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
4 | Interleukin signaling pathway | |||
5 | JAK/STAT signaling pathway | |||
6 | PDGF signaling pathway | |||
7 | Ras Pathway | |||
8 | CCKR signaling map ST | |||
Pathway Interaction Database | GMCSF-mediated signaling events | Click to Show/Hide | ||
2 | IL27-mediated signaling events | |||
3 | Signaling events mediated by PTP1B | |||
4 | IL12-mediated signaling events | |||
5 | Signaling events mediated by TCPTP | |||
6 | Signaling events mediated by HDAC Class I | |||
7 | IL2-mediated signaling events | |||
8 | CXCR4-mediated signaling events | |||
9 | EGF receptor (ErbB1) signaling pathway | |||
10 | IFN-gamma pathway | |||
11 | ErbB1 downstream signaling | |||
12 | ErbB2/ErbB3 signaling events | |||
13 | IL6-mediated signaling events | |||
14 | PDGFR-beta signaling pathway | |||
15 | Neurotrophic factor-mediated Trk receptor signaling | |||
16 | IL23-mediated signaling events | |||
17 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
18 | FGF signaling pathway | |||
19 | RAC1 signaling pathway | |||
20 | Notch-mediated HES/HEY network | |||
21 | IL12 signaling mediated by STAT4 | |||
Reactome | Interleukin-6 signaling | Click to Show/Hide | ||
2 | Senescence-Associated Secretory Phenotype (SASP) | |||
3 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | |||
4 | Transcriptional regulation of pluripotent stem cells | |||
5 | Growth hormone receptor signaling | |||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | Click to Show/Hide | ||
2 | Notch Signaling Pathway | |||
3 | Interferon type I signaling pathways | |||
4 | EPO Receptor Signaling | |||
5 | TGF Beta Signaling Pathway | |||
6 | IL-2 Signaling Pathway | |||
7 | EGF/EGFR Signaling Pathway | |||
8 | IL-4 Signaling Pathway | |||
9 | IL-6 signaling pathway | |||
10 | Signaling of Hepatocyte Growth Factor Receptor | |||
11 | Kit receptor signaling pathway | |||
12 | Nuclear Receptors Meta-Pathway | |||
13 | Estrogen Receptor Pathway | |||
14 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
15 | IL-3 Signaling Pathway | |||
16 | Dopaminergic Neurogenesis | |||
17 | Transcriptional regulation of pluripotent stem cells | |||
18 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
19 | Signaling by SCF-KIT | |||
20 | Interleukin-6 signaling | |||
21 | Growth hormone receptor signaling | |||
22 | JAK/STAT | |||
23 | PDGF Pathway | |||
24 | BDNF signaling pathway | |||
25 | Oncostatin M Signaling Pathway | |||
26 | Adipogenesis | |||
27 | Interleukin-11 Signaling Pathway | |||
28 | AGE/RAGE pathway | |||
29 | Prostate Cancer | |||
30 | TSLP Signaling Pathway | |||
31 | IL-9 Signaling Pathway | |||
32 | IL17 signaling pathway | |||
33 | IL-7 Signaling Pathway | |||
34 | Regulation of Microtubule Cytoskeleton | |||
35 | Leptin signaling pathway | |||
36 | TSH signaling pathway | |||
37 | Cell Differentiation - Index | |||
38 | Cell Differentiation - meta | |||
39 | Signaling by PDGF | |||
40 | NGF signalling via TRKA from the plasma membrane | |||
41 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
42 | MicroRNAs in cardiomyocyte hypertrophy | |||
43 | Physiological and Pathological Hypertrophy of the Heart | |||
44 | Androgen receptor signaling pathway | |||
45 | IL-5 Signaling Pathway |